Enerion, 200 mg 60 pcs.

The drug Enerion is a synthetic compound similar in structure to thiamine, compared to which the molecule has an open thiazole cycle, an additional disulfide bond, and a lipophilic ester.

This modification makes sulbutiamine well soluble in fat, rapidly absorbed from the gastrointestinal tract and easily passes through the BET; unlike thiamine it is able to accumulate in cells of the reticular formation, hippocampus and dentate gyrus, as well as Purkinje cells and glomeruli of the cerebellar granular layer.

Anerion improves coordination of movement and increases resistance to physical stress, increases resistance of cortical structures to repetitive anoxia. The drug is effective in the symptomatic treatment of functional asthenia.

Pharmacokinetics

Sulbutiamine is quickly absorbed, C_max of the drug in plasma is reached 1-2 hours after administration. T_1/2 is about 5 hours. The drug is excreted in the urine.

Indications

Symptomatic treatment of functional asthenia.

Pharmacological effect

The drug Enerion is a synthetic compound, similar in structure to thiamine, in comparison with which the molecule has an open thiazole ring, an additional disulfide bond, and a lipophilic ester.

Thanks to this modification, sulbutiamine is highly soluble in fats, quickly absorbed from the gastrointestinal tract and easily penetrates the BBB; unlike thiamine, it can accumulate in the cells of the reticular formation, hippocampus and dentate gyrus, as well as Purkinje cells and glomeruli of the granular layer of the cerebellar cortex.

While taking Enerion, coordination of movement improves and resistance to physical stress increases, and the resistance of cerebral cortex structures to repeated anoxia increases. The drug is effective in the symptomatic treatment of functional asthenia.

Pharmacokinetics

Sulbutiamine is rapidly absorbed, the Cmax of the drug in the blood plasma is reached 1–2 hours after administration. T1/2 – about 5 hours. The drug is excreted in the urine.

Special instructions

The excipients of Enerion include lactose monohydrate.

As a result, this drug is not recommended for use in persons with lactose intolerance, galactosemia, or glucose/galactose malabsorption syndrome.

Impact on the ability to drive a car and perform work requiring high speed psychomotor reactions. No effect.

Active ingredient

Sulbutiamine

Composition

1 film-coated tablet contains:

Active ingredient:

sulbutiamine 200 mg;

Excipients:

corn starch – 12 mg;

dried starch paste – 40 mg;

glucose (dextrose) anhydrous – 20 mg;

lactose monohydrate – 65.5 mg;

magnesium stearate – 3.5 mg;

talc – 9 mg;

Shell:

sodium bicarbonate – 0.603 mg; sodium carboxymethylcellulose – 0.556 mg; white beeswax – 0.201 mg; titanium dioxide (E171) – 8.43 mg; ethylcellulose – 0.485 mg; Sunset yellow FCF, E110 – 3 mg; glycerol monooleate – 0.242 mg; polysorbate 80 – 0.302 mg; povidone – 0.692 mg; sucrose – 106.956 mg; colloidal silicon dioxide anhydrous (Aerosil 130) – 0.404 mg, talc – 28.21 mg

Pregnancy

According to the results of clinical studies, the drug does not affect fetal development.

However, due to the lack of sufficient clinical data, Enerion is not recommended for use during pregnancy, as well as during breastfeeding, because It is currently unknown whether sulbutiamine is able to pass into breast milk.

Contraindications

Hypersensitivity to any of the components of the drug Enerion.

With caution: persons under 18 years of age (the drug is not recommended for use due to lack of clinical data).

Side Effects

Allergic reactions (the presence of Sunset yellow dye in the drug), digestive disorders, psychoneurological reactions (tremor, headache, agitation, general malaise).

Overdose

Symptoms: excitement with symptoms of euphoria and tremors of the limbs are transient in nature and do not require special treatment.

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

3 years

Manufacturer

Servier Industry Laboratories, France